Bipolar disorder (BP) is a severe and common psychiatric disorder characterized by extreme mood swings. Family, twin and adoption studies strongly support a genetic component. The mode of inheritance is complex and likely involves multiple, as yet unidentified genes. To identify susceptibility loci, we conducted a genome-wide scan with 343 microsatellite markers in one of the largest, well-characterized pedigree samples assembled to date (373 individuals in 40 pedigrees). To increase power to detect linkage, scan statistics were used to examine the logarithm of odds (lod) scores based on evidence at adjacent chromosomal loci. This analysis yielded significant evidence of linkage (genome-wide Po0.05) for markers on 2p13-16. Standard linkage analysis was also supportive of linkage to 2p13-16 (lod ¼ 3.20), and identified several other interesting regions: 4q31 (lod ¼ 3.16), 7q34 (lod ¼ 2.78), 8q13 (lod ¼ 2.06), 9q31 (lod ¼ 2.07), 10q24 (lod ¼ 2.79), 13q32 (lod ¼ 2.2), 14q21 (lod ¼ 2.36) and 17q11-12 (lod ¼ 2.75). In this systematic, large-scale study, we identified novel putative loci for BP (on 2p13-16, 8q13 and 14q21) and found support for previously proposed loci (on 4q31, 7q34, 9q31, 10q21-24, 13q32 and 17q11-12). Two of the regions implicated in our study, 2p13-14 and 13q32, have also been linked to schizophrenia, suggesting that the two disorders may have susceptibility genes in common.
Introduction
Bipolar affective disorder (BP), or manic depression, is a major psychiatric disorder characterized by mania (BPI) or hypomania (BPII) alternating with periods of depression. BP is a major public health concern owing to high lifetime prevalence (0.5-1.5%) and substantial morbidity and mortality: if untreated, the disease can lead to frequent hospitalizations, substance abuse, psychosocial impairment and suicide. Little is known about the etiology of BP, but geneticepidemiological studies support a strong genetic component. Susceptibility to BP is likely governed by multiple genes together with nongenetic influences.
Early linkage studies produced negative or inconsistent results, underscoring pitfalls in linkage analysis of complex psychiatric traits. [1] [2] [3] [4] Recent data generated with improved methodologies and extensive genome coverage have implicated several chromosomal regions as potential sites for BP genes, most notably 1q31-32, 5 21q22, 14 22q11-13 15 and Xq24-27. 16 Even with these improvements, conflicting reports and methodological uncertainties indicate that these are not confirmed, compelling findings. 3, 17 In previous, more limited studies, we reported evidence of linkage to 21q 22 14, 18, 19 and nonreplication of proposed loci on 18p11 20 and Xq27-28.
21,22
Here, we report a comprehensive, whole-genome scan in a large series of pedigrees with high density of BP and other mood disorders. This sample includes the families studied in our previous 21q 18 and Xq 21, 22 studies, and 40 of the pedigrees reported in our 18p study 20 (as determined by power to detect linkage; see Methods). We present evidence for novel, unreported BP susceptibility loci, support for previously reported loci, and possible overlap between loci implicated in BP and schizophrenia. Results are discussed in the light of previous studies and in consideration of methodological and etiological complexities.
Methods

Subjects
A detailed description of the pedigree set, including ascertainment, diagnostic procedures and affection status models, is given elsewhere. 23 Briefly, our overall sample consists of 1508 individuals (Caucasian, age 16 or over) in 57 extended pedigrees with high density of BP. We required at least two members per pedigree (including the proband) with a lifetime diagnosis of mania (BPI or schizoaffective disordermanic type; the BPI category comprised nearly 90% of manic syndromes in this sample, with schizoaffective disorder accounting for a mere 10%). The pedigrees were obtained in the US (39 pedigrees) and Israel (18 pedigrees) using the same research protocol. US and Israeli pedigrees displayed similar rates of BP and related mood disorders. The protocol and the consent forms were approved by the Institutional Review Boards at the data collection sites.
The clinical evaluation was based on personal interviews using the Lifetime Version of the Schedule for Affective Disorders and Schizophrenia 24 modified for bipolar affective disorders (SADS-LB) and supplemented by family history information and medical records. Best estimate consensus diagnoses were made by independent diagnosticians using all available sources of information. Diagnostic determinations were based on the Research Diagnostic Criteria (RDC) 25 and were made blind to familial relationships, clinical status of other relatives, and genotypic information.
To address the question of phenotypic uncertainty, we used several affection status definitions, or diagnostic models. The 'affected' category was broadened progressively from narrow to broader phenotypic boundaries using three diagnostic models. BP1: manic syndrome, mostly BPI; BP2: same as BP1 plus BPII; BP3: same as BP2 plus recurrent major depressive disorder (MDD) (including some cases of recurrent schizoaffective, mainly affective-depressed only). These disorders aggregate in families of bipolar probands and are therefore considered part of the bipolar 'spectrum'. BP1 represents the 'core' phenotype (narrowest disease definition), with the highest relative risk. In all models, the 'unaffected' category consists mainly of 'never mentally ill'. Mental disorders that do not aggregate in families of BP probands are also included in this category. The 'uncertain' category in the analysis included all affective disorders that are not considered 'affected' under a particular model plus some nonaffective conditions that show increased rates in the families of patients with some forms of affective illness but whose familial relation to BP is unclear (acute and subacute schizophrenic disorder, and unspecified psychosis).
Our goal was to maximize the power to detect susceptibility genes, while minimizing the cost. As described, 18, 19 we used a simulation algorithm to select for genotyping a subset of the overall pedigree sample, which gleaned the bulk of the genetic information under the models tested. Because the disease phenotype in our pedigrees is segregating in largely a vertical mannerFas customary in studies of extended multiplex pedigrees, we sought families with unilineal transmissionFour genotyping strategy was optimized accordingly. The algorithm selected affected individuals and connecting lineal pedigree members, while excluding other individuals, including unaffected siblings and married-in spouses. It has been shown that genotyping can be made more efficient by excluding founders and married-in individuals, 26 though their elimination may cause an increase in the genome-wide false-positive rate. Also discarded were pedigrees missing DNA samples from critical individuals. The genotyped subset thus created consisted of 373 individuals from the 40 most informative pedigrees, 307 of whom were affected (an average of seven or eight affected individuals per pedigree). The distribution of diagnoses was as follows: 119 individuals with BPI, 90 with BPII and 98 with recurrent MDD.
Genotyping
For the genome-wide screening, we used semiautomated fluorescence-based genotyping with 343 microsatellite markers arranged in multiplex panels. The average heterozygosity and polymorphic information content (PIC) of these markers is 0.75 and 0.72, respectively. The average marker spacing is about 10 cM (range: 0 cM, at D4S335 and D4S408 to 27.5 cM, between D12S-PAH and D12S395). The genotyping procedure is described in detail elsewhere. 27 Briefly, PCR reactions were aliquoted onto 384-well plates using a TECAN Genesis robot and cycled on MJ thermocyclers. PCR products were separated and detected on ABI 377 DNA sequencers, and then analyzed using GeneScan v. 2.1 (PerkinElmer). Allele sizes were called automatically with the ABI software package GENOTYPER v. 2 (PerkinElmer), and were then double-checked visually by two different readers without any knowledge of the diagnosis of a given individual. All the genotypes were then stored in LABMAN, 28 a FOXPRO 2.0 database.
Linkage analysis
Marker data were checked for Mendelian inconsistencies using the Pedcheck program. 29 Ambiguous marker phenotypes were deleted prior to linkage analysis. Biological kinship was examined using the RelCheck program. 30 Allele frequencies were estimated from all genotyped individuals using the Gconvert program (http://www2.qimr.edu.au/ davidD). Linkage was evaluated using the three affection status definitions, BP1, BP2 and BP3.
Two-point parametric analysis was carried out using the MLINK program from the FASTLINK package. 31 This analysis calculates the likelihood of linkage between a given marker and the disease loci vs the likelihood of no linkage assuming a specified genetic model. Results are then tabulated as log of odds (lod) score. Since the genetic models are unknown for BP, both dominant and recessive transmissions were tested in our analyses, even though the sample selection was optimized to be more powerful for detecting dominantly transmitted predisposing alleles (see Subjects). For the dominant model, we used the same parameters described in previous publications. 14, 18, 19 This model assumes a disease allele frequency of 0.01, and a penetrance of 80% for gene carriers and 1% for noncarriers. A corresponding recessive model assumes the same penetrance in gene carriers and noncarriers but a disease allele frequency of 0.10. While these analysis models do not realistically describe potential inheritance at a given susceptibility locus, their use has nonetheless been shown to be powerful for analysis purposes. 32 To reduce the impact of nonpenetrant disease alleles upon the linkage analysis, all unaffected ones were coded as unknown. Considering the possibility of locus heterogeneity within large pedigrees, we used parametric analyses to evaluate both whole pedigrees and whole pedigrees broken into nuclear families. The A-test of linkage homogeneity 33 was applied using the HOMOG program. 34 Multipoint analyses were conducted using the same analytical model that was used to produce the two-point results. Due to computational constraints, only two adjacent markers were employed for the analysis (ie three-point analysis) of entire pedigrees using MLINK. In contrast, all markers were included for analysis of nuclear families using the Genehunter program. To minimize the false rejection of linkage in multipoint analysis, 35 the disease locus was placed outside the region of the two tested markers in the three-point analysis of entire pedigreesFthis is analogous to the multipoint linkage analysis algorithm of Goring and Terwilliger 36 For, alternatively, we allowed for heterogeneity when all markers were used in the nuclear family analyses.
Affected sib-pair (ASP) analysis was performed using version (2.0) of MAPMAKER/SIBS, 37 which uses the maximum-likelihood score (MLS) approach. The identity by descent (IBD) distribution (ie sharing 2, 1, or 0 allele) can be estimated between sib pairs and then compared with the IBD distribution under the assumption of no linkage, that is 0.25, 0.5 and 0.25. The MLS is then calculated by comparison between the estimated IBD distribution and the null distribution at no linkage. Since this analysis can only be performed in the nuclear families, and each nuclear family is not totally independent, we only analyze the first sib pair from each nuclear family.
To increase the power to detect linkage, we utilized scan statistics to evaluate the evidence for linkage throughout the genome. 38 This procedure combines the lod score for a marker with those of the surrounding markers. Markers (L) between one and eight were combined in the analysis. To reduce the amount of missing data for founders, unknown founder genotypes were reconstructed (imputed) from the original genotype data using the SIMWALK2 program. 39 The 'sampling' feature of this program uses the available data are calculate the missing genotype data in proportion to the likelihood of the data conditional on the given marker data. The missing genotype data are then sampled according to these proportions. The data were sampled 500 times, thus creating 500 replicates with genotyped founders. The SIMULATE2 program, a modified version of the SIMULATE program, 40 was then used to drop the genotypes from founders to offspring without regard to affection status, to create null replicates of the original data for each of the 500 replicates. Genotypes were kept only for those individuals and markers which were originally genotyped in the study. Two-point parametric linkage analysis was then carried out for the original and each of the 500 replicate data sets for dominant and recessive models as described earlier. For each marker and each family (in the observed and simulated data), the lod score was maximized over recombination fraction values ranging from 0.00 to 0.50 and over dominant/recessive modes of inheritance. Scan statistics were calculated for the original data and the null replicates, where the latter served to evaluated genome-wide P-values for scan statistics.
Results
Parametric analysis
Two-point lod scores meeting statistical criteria proposed by Lander and Kruglyak 2 for suggestive linkage in genome scans (lodX1.9) are shown in Table 1 . Two loci gave lods of43, D2S441 at 2p13-16 (lod ¼ 3.2; BP2, dominant model, nuclear-family analysis; this locus also gave a lod ¼ 1.94 under BP1, recessive model, whole-pedigree analysis) and D4S1625 at 4q31 (lod ¼ 3.16; BP3, dominant model, nuclear-family analysis). These values approach significant linkage (lod ¼ 3.3). 2 The other loci with evidence of suggestive linkage (ie, lod X 1.9) are D3S2398 (BP1, recessive model, whole-pedigree analysis; this locus also gave lod ¼ 1.02 under BP1, dominant model, nuclear-family analysis), D8S2323 (BP2, dominant model, whole-pedigree analysis), D9S938 (BP1, dominant model, nuclear-family analysis; also, lod ¼ 1.09 under BP1, dominant model, whole-pedigree analysis) D10S1225 (BP2, dominant model, whole-pedigree analysis), D10S169 (BP1, dominant model; BP3, dominant model, nuclearfamily analysis) and D17S921 (BP1, dominant model, whole-pedigree analysis). The corresponding regions are 3q27-28, 8q13, 9q31, 10q21, 10q24 and 17q11-12.
The contribution of individual pedigrees to the overall maximum lod scores at these loci was modest (lodo1), suggesting that multiple families contributed to these lod scores.
The multipoint lod scores for these loci (same models as in the two-point analysis) were as follows: 1.64 (BP2, dominant model, nuclear-family analysis) and 1.63 (BP1, recessive model) at 2p13-16; 2.52 at 4q31; 0.16 at 3q27-28; 2.06 at 8q13; 2.07 at 9q31; 1.98 at 10q21; 2.33 (for BP1) and 1.78 (for BP3) at 10q24, and 2.75 at 17q11-12 (D17S921 and D17S900). These results are generally consistent with the two-point analysis, with the exception of 3q27-28. It has been shown that multipoint parametric linkage analysis of complex traits may result in deflated lod scores. 35 Modest two-point lod scores (lod of 41 but o1.7) were observed at several other regions (not shown). Two of these regions, 6q16 and 7q34, were potentially interesting because lods41 were observed at adjacent loci: lod of 1.44 and 1.11 at D6S1031 and D61270, respectively (BP1, dominant model, nuclear-family analysis), and lod of 1.10 and 1.17 at D7S2847 and D7S1804 (BP2, dominant model, whole-pedigree analysis). The corresponding multipoint lod scores for the two regions were 1.43 and 1.28.
The A-test 33 failed to reject the hypothesis of linkage homogeneity for any of the marker loci. However, this test is not a very powerful statistic for analysis of disorders with unknown mode of inheritance because the model errors are confounded with the recombination fraction estimates. Given the likely heterogeneous nature of BP, we do not suggest that failure to reject the null hypothesis implies that it should be accepted.
A graphical presentation of parametric lod scores, illustrating the signal-to-noise ratio, is given in Figure 1 (whole-pedigree analysis) and Figure 2 (nuclear-family analysis).
ASP analysis
Multipoint lod scores indicative of suggestive linkage in genome scans using ASP analysis (lod X2.2) 2 were observed on 7q34 near D7S1824 (lod of 2.78 with BP2) 13q32 near D13S779 (lod of 2.2 with BP2), and 14q21 near D14S306 (lod of 2.36 with BP2). The corresponding lod score curves are shown in Figure 3 . These results, together with other, more modest findings (lod of 41 buto1.8), are shown in Table 2 . The other, more modest lod scores occured on 1p36 near D1S552 (lod score ¼ 1.71 with BP3), 2p13-16 near D2S441 (lod score ¼ 1.59 with BP2), 7q31-33 between D7S2847 and D7S1799, 8p23 near D8S1458 (lod score ¼ 1.77 with BP2), 9q21-22 between D9S922 and D9S910 (lod score ¼ 1.40 with BP1), 10q24 between D10S1248 and D10S169 (lod score ¼ 1.57 with BP1), 11p15 near D11S2362 (lod score ¼ 1.44 with BP3), 14q32 (lod ¼ 1.36 with BP1) and 18q12-21 between D18S535 and D18S851 (lod ¼ 1.18 with BP1). The two-point ASP lod scores (not shown) were smaller than the multipoint results.
Scan statistics
The results are presented in Table 3 . The maximum single-marker statistic (S L ¼ 1 ), or in this case simply the lod score, was 3.123 (empirical genome-wide Pvalue ¼ 0.032) with marker D2S441 (this lod score was obtained under the dominant model and BP2). The best scan statistic (minimum empirical P-value) for any number of contiguous markers was found with two markers that included D2S441 and D2S1394. After adjusting for the testing of scan statistics of various lengths, the genome-wide P-value for this scan statistic was 0.048 (ie, statistically significant). This was the only statistically significant result using scan statistics, in this study (the next best scan statistic occurs on chromosome 9, with P ¼ 0.394).
Discussion
The overall results identify several chromosomal regions that may harbor BP susceptibility loci: 2p13-16, 4q31, 7q34, 8q13, 9q31, 10q21-24, 13q32, 14q21 and 17q11-12. Regions 2p13-16 and 4q31 display lod scores43. The evidence on 2p13-16 appears to be significant using scan statistics, and is also supported by standard parametric linkage analysis; the evidence on 4q31 approaches significance. 2 The other regions mentioned display suggestive linkage. 2 The highest lod scores were largely obtained under a dominant model of inheritance. Our pedigrees show primarily a 'dominant-like' pattern, and our genotyping strategy was optimized accordingly (see Methods). Although the exact mode of transmission of BP is unknown, some studies using segregation analysis advocate a role for dominant inheritance. 41, 42 Inter- Evidence for bipolar disorder loci J Liu et al the structure of our pedigrees, where most of the meioses connect family members across, not within sibships.
For parametric linkage analysis, we used both whole-pedigree and nuclear-family analyses. Splitting whole pedigrees into nuclear families can mitigate effects of intra-pedigree heterogeneity, thus improving the chance to detect linkage. However, loss of information on familial relationships can reduce statistical power. Our results on 2p, 4q, 9q and 10q24, where the evidence of linkage comes primarily from nuclear-family analysis, may be indicative of the first scenario. The second effect might be reflected in the results on 8q, 10q21 and 17q, where support for linkage is derived solely from whole-pedigree analysis. Nearly all of our strongest results (significant or suggestive linkage) 2 were obtained with narrow disease definitions (BP1, BP2). Narrowly defined phenotypes are viewed as more homogeneous, with a stronger familial component (higher relative risk ratios) and, possibly, a more predictable genotype-phenotype relationship, than broadly defined phenotypes.
Of the 40 pedigrees analyzed in this study, 29 were ascertained in the US (European ancestry) and 11 in Israel (Middle-Eastern extraction). The pattern of results was similar in the two samples (data not shown), though lod scores in the Israeli sample were generally smaller, probably due to the smaller sample (ie, reduced statistical power). Larger samples are required to assess possible differences among populations.
Linkage evidence at 2p, 8q and 14q appears to be novel. Support for a putative locus on 8q was reported in a sample composed of German, Israeli and Italian families, though at a more distal location, on 8q24. 43 Evidence at 4q, 7q, 9q, 10q, 13q and 17q is consistent with previous linkage findings. Support for linkage to 4q was reported in Old Order Amish, 44 Australian 45 and US 46 pedigrees. A more proximal location, on 4q12-13, was reported in UK-Irish families. 47 Possible linkage to 7q was observed in the NIMH genetics initiative pedigree series 48 and in another series of US pedigrees. 5 Modest support for linkage to 9q was observed in the NIMH genetics initiative pedigree sample. 48 Our finding at 10q21-24 is consistent with similar findings in another series of US pedigrees 15 and in German 9 and UK-Irish 47 families. Support for linkage to 13q was reported in two separate series of US pedigrees 5, 15 and in a large Australian pedigree 49 (though at a more proximal site, on 13q14). Modest support for linkage to 17q was observed in a series of UK-Irish families. 47 We also note that reported linkages to other chromosomal regions, including 1q, 4p, 6p, 10p, 12q, 18p, 18q and Xq (see Introduction), are not clearly supported by our data. We found, though, modest support for a previously reported linkage on 18q. 13 In a previous, partial genome scan, we reported evidence for a putative BP locus on chromosome 21q22 in a single large pedigree.
14 There was little, if any evidence of linkage among the other pedigrees in that sample. In the present scan, there is no apparent linkage to 21q in the sample as a whole. However, in other analyses of this sample, we detected evidence of linkage (parametric lod scores of 43) with a dense array of markers (average marker spacing o2 cM) spanning the 21q22 region. 18, 19 In those analyses, the marker with the highest lod score was B8 cM away from the closest 21q marker in the present scan data. This example illustrates the potential for type 2 errors in genome scans at B10 cM marker densityFin particular, incidental gaps in marker coverage (in contradiction to high-density marker spacing, as in our previous, targeted studies of 21q 18, 19 ). Nonallelic heterogeneity and modest gene effects may further undermine linkage detection. The putative linkage to 21q22 is supported by other, independent studies. 5, 15, 48, [50] [51] [52] [53] Two of the regions presumed linked in our study (2p and 13q) have also been implicated in schizophrenia. Support for linkage to schizophrenia on 2p was found in Micronesian pedigrees. 54 Region 13q was reportedly linked to schizophrenia in US 55 and Canadian 56 pedigrees, and to BP in US 5, 15 and Australian pedigrees. 49 Reports that BP and schizophrenia may have susceptibility genes in common are consistent with the notion of a shared diathesis for the major psychoses. 17, 57 They may also provide cross-validation of genetic findings and a basis for a broader view of disease phenotypes. Although BP and schizophrenia do not show significant coaggregation in families, there is evidence for overlap. [58] [59] [60] Specifically, relatives of both bipolar and schizophrenic patients are at increased risk for schizoaffective disorder (a condition combining clinical features of both disorders) and depression. Also, relatives of schizoaffective patients show elevated rates of BP, schizophrenia and depression. Of course, the notion of common genes for the two disorders is a mere hypothesis requiring proof, specifically gene discovery and demonstration of a causal link to both disorders.
False-positive findings are not uncommon in the search for complex disease genes. Our results (and those reported by others) must be qualified accordingly. To enhance the prospect of linkage detection, and to best cover the most likely modes of inheritance, we employed several diagnostic and genetic models. This may have led to inflated linkage signals due to multiple testing. However, the fact that some of these tests are correlatedFfor example, there is some overlap in diagnostic models (BP1 is nested in BP2, and BP2 is nested in BP3)Fpartially offsets the multiple test effect because these tests are not truly independent. There is no straightforward, adequate statistical method to correct multiple test effects in these circumstances. We are not claiming that our linkage signals prove the existence of BP susceptibility genes. Rather, we advise caution while Evidence for bipolar disorder loci J Liu et al pointing to supporting evidence. Our genotyping strategy, which was optimized for cost-efficiency, entails another potential source of error due to the exclusion of some individuals (see Methods). A follow-up study including all individuals in the sampling frame should cast light on this issue. In a prior study, we applied this approach to our linkage finding on 21q22, 14, 18 and were able to confirm the initial result. 19 Although we emphasize the provisional nature of our findings, the strength of linkage signals compared to other regions in our genome scan, the apparent corroborating evidence from other studies for some of our results, and the concurrence of some linkage signals using different analytical models provide some measure of confidence. We also note that our sample is larger than most previous data sets; small samples are more susceptible to both false-positive and false-negative findings due to reduced power and random statistical fluctuations. 3 Scan statistics, 38 which showed significant linkage to 2p13-16 in this sample, tend to add power to linkage analysis if a lod score peak is a true peak. For example, when this method was applied to a genome scan with autism, a susceptibility region was found, which was missed with standard approaches. 38 The gain in power is between 10 and 20%. 61 In summary, we report evidence for putative loci that may predispose to BP. Some of these loci are novel, others have support from prior studies. Some of the regions implicated in this study overlap with candidate regions for schizophrenia, raising the possibility of some genetic continuum for these disorders. Conclusive evidence for susceptibility loci will require additional confirmation from other studies and, ultimately, cloning of putative genes and proving their relationship to the disease. Recent advances including the Human Genome Project and detection of susceptibility genes for other complex disorders such as noninsulin-dependent diabetes mellitus 62 and Crohn's disease (an inflammatory bowel condition) 63 suggest that this is a goal worth pursuing.
